OGN

Organon's stock has been impacted by several events in the past six months. In late April 2026, the stock surged due to a proposed acquisition by Sun Pharmaceutical Industries for $11.75 billion, leading to the suspension of financial guidance and cancellation of earnings calls. Organon reported its Q1 2026 earnings on April 30, 2026, with revenue of $1.46 billion and adjusted EPS of $0.71, missing analyst estimates. In February 2026, the stock saw a lift after an independent audit review found no improper conduct regarding biosimilar purchases, but Q4 and full-year 2025 earnings revealed a net loss and flat 2026 guidance.